Business

Exclusive Rachel Cohrs

The Catholic hospital system Ascension is running a Wall Street-style private equity fund

A STAT Investigation Rachel Cohrs

How America’s largest Catholic hospital system is moonlighting as a private equity firm

Pharma Olivia Goldhill

Latest psilocybin patent highlights the swirling battle over psychedelics intellectual property

A STAT Investigation Eric Boodman

Selling certainty: In a sea of skeptics, this physician was one of fibromyalgia patients' few true allies. Or was he?

Jonathan Saltzman — Boston Globe

Lawyers for Henrietta Lacks estate say more companies to be sued over use of her cells

Business Andrew Joseph

Third member of FDA expert committee resigns over controversial Alzheimer’s therapy decision

Business Andrew Joseph

Member of FDA’s expert panel resigns over controversial Alzheimer’s therapy approval

Exclusive Adam Feuerstein and Damian Garde

Martin Shkreli’s longtime friend wants to undo his 4,000% price hike. But first he’ll have to finally oust the ‘pharma bro’

Business Alicia Diaz

Medical device firms’ payments to doctors far outstripped those from pharma, study shows

Hospitals Liz Kowalczyk, Sarah L. Ryley, Mark Arsenault, and Patricia Wen — Boston Globe

Boston’s hospital chiefs moonlight on corporate boards at rates far beyond the national level

Pharma Olivia Goldhill

Behind the scenes, companies helping big Covid-19 vaccine makers are getting rich

Casey Ross and Erin Brodwin

‘What was left for Haven?’: How Amazon’s health ambitions devoured Haven’s plans

Health Tech Elizabeth Cooney

As health tech flourished, Teladoc and Livongo saw an opportunity to ‘accelerate,’ executives say

Biotech Elizabeth Cooney

Foundation Medicine wins FDA approval for liquid biopsy able to detect mutations in multiple cancers 

Biotech Adam Feuerstein

The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review

Biotech Damian Garde and Matthew Herper

Coles-led Cerevel Therapeutics to raise $445 million to develop brain drugs with fewer side effects

Biotech Adam Feuerstein

The biotech scorecard for the third quarter: 14 stock-moving events to watch

Biotech Adam Feuerstein

FDA rejects Intercept Pharma’s drug for NASH

Biotech Adam Feuerstein

Zogenix wins approval for new drug to treat rare type of childhood epilepsy

Special Report David Barboza — The Wire

After a bribery scandal in China, GSK found a suspected whistleblower. The real one is still waiting in the shadows

Biotech Adam Feuerstein

A crucial study of Bellus Health’s chronic cough drug reads out soon. Here’s what you need to know

Business Elizabeth Cooney

A ‘semi-wartime’ effort: Thermo Fisher COO on adapting the business to a Covid-19 world

Biotech Adam Feuerstein

Court invalidates Biogen’s patent on blockbuster multiple sclerosis drug

Biotech Elizabeth Cooney

Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it

Business Elizabeth Cooney

‘One thing cancer patients don’t generally have is time’: New cancer research leader brings urgency to Sanofi

Biotech Elizabeth Cooney

Startup Spotlight: Aiming to speed precision cancer therapies to children

Special Report Erin Brodwin and Casey Ross

Two years of halting progress and high turnover preceded Atul Gawande’s exit as Haven CEO

Business Casey Ross

Gawande says leaving Haven CEO job will allow him to focus on Covid-19

Business Casey Ross and Erin Brodwin

Atul Gawande to depart as CEO of splashy health venture. Is it ‘a death knell’?